JAK-inhibition as a therapeutic strategy for refractory primary systemic vasculitides.
作者信息
Khan Sujoy
机构信息
Consultant immunologist, Castle Hill Hospital, Cottingham, UK.
出版信息
Clin Med (Lond). 2021 Mar;21(2):e241-e242. doi: 10.7861/clinmed.Let.21.2.2.
Abstract
摘要
相似文献
1
JAK-inhibition as a therapeutic strategy for refractory primary systemic vasculitides.JAK抑制作为难治性原发性系统性血管炎的一种治疗策略。
Clin Med (Lond). 2021 Mar;21(2):e241-e242. doi: 10.7861/clinmed.Let.21.2.2.
2
Cutaneous and systemic vasculitides in dermatology: a histological perspective.皮肤病学中的皮肤和系统性血管炎：组织学视角
G Ital Dermatol Venereol. 2018 Apr;153(2):185-193. doi: 10.23736/S0392-0488.18.05886-8. Epub 2018 Jan 24.
3
Current concept and epidemiology of systemic vasculitides.系统性血管炎的当前概念与流行病学
Allergol Int. 2014 Dec;63(4):505-13. doi: 10.2332/allergolint.14-RAI-0778. Epub 2014 Oct 25.
4
5
Testing for antineutrophil cytoplasmic antibodies (ANCAs) in patients with systemic vasculitides and other diseases.
Ann Rheum Dis. 2017 Aug;76(8):e23. doi: 10.1136/annrheumdis-2016-210890. Epub 2016 Dec 23.
6
Primary Systemic Vasculitides as a Cause of Group IV Pulmonary Hypertension.原发性系统性血管炎导致的 IV 型肺动脉高压。
Anatol J Cardiol. 2023 Dec 1;27(12):677-687. doi: 10.14744/AnatolJCardiol.2023.3650. Epub 2023 Nov 21.
7
Clinical and anamnestic features of patients with systemic vasculitis: a single-center retrospective study.系统性血管炎患者的临床和病史特征：一项单中心回顾性研究。
Rheumatol Int. 2024 Apr;44(4):687-692. doi: 10.1007/s00296-024-05533-4. Epub 2024 Feb 6.
8
Childhood systemic vasculitis.儿童全身血管炎。
Best Pract Res Clin Rheumatol. 2017 Aug;31(4):558-575. doi: 10.1016/j.berh.2017.11.009. Epub 2017 Dec 23.
9
Cardiac involvement and cardiovascular risk factors in pediatric primary systemic vasculitides.儿科原发性系统性血管炎的心脏受累和心血管危险因素。
Clin Rheumatol. 2023 Mar;42(3):673-686. doi: 10.1007/s10067-022-06434-2. Epub 2022 Nov 12.
10
Pregnancy Outcomes in Systemic Vasculitides.系统性血管炎的妊娠结局。
Curr Rheumatol Rep. 2020 Aug 26;22(10):63. doi: 10.1007/s11926-020-00940-5.
本文引用的文献
1
An update on the general management approach to common vasculitides.常见血管炎的一般治疗方法的最新进展。
Clin Med (Lond). 2020 Nov;20(6):572-579. doi: 10.7861/clinmed.2020-0747.
2
Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. Correspondence on 'Tofacitinib for polyarteritis nodosa: a tailored therapy' by Rimar .托珠单抗治疗结节性多动脉炎：一项系统文献综述。关于Rimar所著“托法替布治疗结节性多动脉炎：一种量身定制的疗法”的通信。
Ann Rheum Dis. 2022 Oct;81(10):e204. doi: 10.1136/annrheumdis-2020-218710. Epub 2020 Sep 9.
3
A pilot study of tofacitinib for refractory Behçet's syndrome.托法替布治疗难治性白塞病的一项试点研究。
Ann Rheum Dis. 2020 Nov;79(11):1517-1520. doi: 10.1136/annrheumdis-2020-217307. Epub 2020 May 27.
4
Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis.托法替布成功缓解一名合并溃疡性结肠炎的难治性大动脉炎患者的病情。
Ann Rheum Dis. 2020 Aug;79(8):1125-1126. doi: 10.1136/annrheumdis-2019-216606. Epub 2020 Mar 25.
5
Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis.大血管血管炎外周免疫表型变化与临床特征的显著相关性。
Arthritis Res Ther. 2019 Dec 30;21(1):304. doi: 10.1186/s13075-019-2068-7.
6
Intestinal Behçet's Disease with Primary Myelofibrosis Involving Trisomy 8.原发性骨髓纤维化伴三体 8 所致肠贝赫切特病。
Acta Haematol. 2019;142(4):253-256. doi: 10.1159/000501019. Epub 2019 Jul 10.
7
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.巴瑞替尼治疗自身炎症性干扰素病的 JAK1/2 抑制作用。
J Clin Invest. 2018 Jul 2;128(7):3041-3052. doi: 10.1172/JCI98814. Epub 2018 Jun 11.
8
Tofacitinib for polyarteritis nodosa: a tailored therapy.托法替布用于结节性多动脉炎：一种个体化治疗。
Ann Rheum Dis. 2016 Dec;75(12):2214-2216. doi: 10.1136/annrheumdis-2016-209330. Epub 2016 Aug 24.
9
Th1 and Th17 cytokines drive inflammation in Takayasu arteritis.Th1 和 Th17 细胞因子驱动 Takayasu 动脉炎的炎症反应。
Arthritis Rheumatol. 2015 May;67(5):1353-60. doi: 10.1002/art.39037.
Zotero 插件